尼可地尔联合二甲双胍治疗2型糖尿病合并冠心病患者的疗效和安全性观察

doi:10.3760/cma.j.issn.1007-1245.2023.07.011

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (7): 936-939.DOI: 10.3760/cma.j.issn.1007-1245.2023.07.011

尼可地尔联合二甲双胍治疗2型糖尿病合并冠心病患者的疗效和安全性观察

康杰¹ 张建建² 张伟东³ 张岳⁴ 黄杲德⁴

¹济南市民族医院内科，济南　250012；²济南市第二人民医院内科，济南　250000；³济南市民族医院老年医学科，济南　250012；⁴济南市民族医院全科医学，济南　250012

收稿日期:2022-12-14 出版日期:2023-04-01 发布日期:2023-04-28
通讯作者: 张建建，Email：120566609@qq.com
基金资助:
山东省医药卫生科技发展计划项目（202103011061）

Efficacy and safety of nicorandil combined with metformin in the treatment of type 2 diabetes mellitus complicated with coronary heart disease

Kang Jie¹, Zhang Jianjian², Zhang Weidong³, Zhang Yue⁴, Huang Gaode⁴

¹Internal Medicine, Jinan Minzu Hospital, Jinan 250012, China; ²Internal Medicine, Jinan Second People's Hospital, Jinan 250000, China; ³Department of Geriatric Medicine, Jinan Minzu Hospital, Jinan 250012, China; ⁴General Practice, Jinan Minzu Hospital, Jinan 250012, China

Received:2022-12-14 Online:2023-04-01 Published:2023-04-28
Contact: Zhang Jianjian, Email: 120566609@qq.com
Supported by:
Health Science and Technology Development Program of Shandong Province (202103011061)

摘要/Abstract

摘要：

目的　探究尼可地尔联合二甲双胍治疗2型糖尿病合并冠心病患者的疗效和安全性。方法　本研究为随机对照试验。选取济南市民族医院内科2021年6月至2022年1月收治的92例2型糖尿病合并冠心病患者作为研究对象，采用随机数字表法分为联合组和常规组，均46例。常规组女26例，男30例，年龄50～80（69.41±8.02）岁；联合组女25例，男31例，年龄56～79（68.74±7.79）岁。常规组口服二甲双胍片治疗，联合组口服二甲双胍片+尼可地尔治疗。治疗2个月后评估两组血糖指标、心功能指标［左心室舒张末期容积指数（LVED-VI）、左心室射血分数（LVEF）］、疗效，记录药物不良反应发生率。采用t检验、χ²检验、秩和检验。结果　治疗后，联合组餐后2 h血糖、空腹血糖低于常规组［（8.14±0.61）mmol/L比（9.89±1.04）mmol/L，（6.10±0.78）mmol/L比（6.89±0.90）mmol/L］（t=4.499，P<0.001；t=9.844，P<0.001）。两组治疗后LVEF均高于治疗前，且联合组LVEF高于常规组［（48.37±6.02）%比（44.12±5.81）%］（t=2.205，P=0.030）；两组治疗后LVED-VI均低于治疗前，且联合组LVED-VI低于常规组［（63.42±9.13）比（67.29±8.93）］（t=3.696，P<0.001）。经秩和检验，联合组疗效优于常规组，差异有统计学意义（Z=2.049，P=0.040）。两组不良反应发生率比较差异无统计学意义（χ²=0.449，P=0.503）。结论　尼可地尔联合二甲双胍治疗2型糖尿病合并冠心病患者效果优越，改善患者的心功能，且安全性良好。

关键词:

尼可地尔, 二甲双胍, 2型糖尿病, 冠心病, 安全性

Abstract:

Objective　To explore the efficacy and safety of nicorandil combined with metformin in the treatment of type 2 diabetes mellitus complicated with coronary heart disease. Methods　It was a randomized controlled trial. A total of 92 patients with type 2 diabetes mellitus complicated with coronary heart disease admitted to Internal Medicine, Jinan Minzu Hospital from June 2021 to January 2022 were selected as the research objects. They were divided into a combined group and a conventional group by the random number table method, with 46 cases in each group. In the conventional group, there were 26 females and 30 males, aged 50-80 years, with an age of (69.41±8.02) years old. In the combined group, there were 25 females and 31 males, aged 56-79 years, with an age of (68.74±7.79) years old. The conventional group was treated with metformin tablets, and the combined group was treated with metformin tablets plus nicorandil. After 2 months of treatment, the blood glucose indexes, cardiac function indexes [left ventricular end-diastolic volume index (LVD-VI) and left ventricular ejection fraction (LVEF)], and efficacies of the two groups were evaluated, and the incidence of adverse drug reactions was recorded. t test, χ² test, and rank sum test were used. Results　After treatment, the 2 h postprandial blood glucose and fasting blood glucose in the combined group were lower than those in the conventional group [(8.14±0.61) mmol/L vs. (9.89±1.04) mmol/L, (6.10±0.78) mmol/L vs. (6.89±0.90) mmol/L] (t=4.499, P<0.001; t=9.844, P<0.001). The LVEF after treatment was higher than that before treatment in both groups, and the LVEF in the combined group was higher than that in the conventional group [(48.37±6.02) % vs. (44.12±5.81) %] (t=2.205, P=0.030). The LVED-VI after treatment was lower than that before treatment in both groups, and the LVED-VI in the combined group was lower than that in the conventional group [(63.42±9.13) vs. (67.29±8.93)] (t=3.696, P<0.001). The rank sum test showed that the efficacy of the combined group was better than that of the conventional group, with a statistically significant difference (Z=2.049, P=0.040). There was no statistically significant difference in the incidence of adverse reactions between the two groups (χ²=0.449, P=0.503). Conclusion　Nicorandil combined with metformin in the treatment of type 2 diabetes mellitus complicated with coronary heart disease has superior hypoglycemic effect, and improves the cardiac function, with good safety.

Key words:

Nicorandil, Metformin, Type 2 diabetes mellitus, Coronary heart disease, Security

康杰张建建张伟东张岳黄杲德.

尼可地尔联合二甲双胍治疗2型糖尿病合并冠心病患者的疗效和安全性观察 [J]. 国际医药卫生导报, 2023, 29(7): 936-939.

Kang Jie, Zhang Jianjian, Zhang Weidong, Zhang Yue, Huang Gaode.

Efficacy and safety of nicorandil combined with metformin in the treatment of type 2 diabetes mellitus complicated with coronary heart disease [J]. International Medicine and Health Guidance News, 2023, 29(7): 936-939.

参考文献

[1] 滕雅娟,唐瑞强,张燕,等.T2DM患者HbA1c水平和胰岛素治疗对认知功能的影响[J].贵州医药,2017,41(5):474-476. DOI:10.3969/j.issn.1000-744X.2017.05.009.
[2] 沈俊红,刘艳,朱曦,等.2型糖尿病轻度认知功能障碍患者执行功能的研究[J].癫痫与神经电生理学杂志,2020,29(4):205-208.
[3] Blom-Høgestøl IK, Mala T, Kristinsson JA, et al. Changes in bone quality after Roux-en-Y gastric bypass: a prospective cohort study in subjects with and without type 2 diabetes[J]. Bone, 2020, 130:115069. DOI: 10.1016/j.bone.2019.115069.
[4] Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control[J]. Endocr Pract, 2009, 15(6):540-559. DOI: 10.4158/EP.15.6.540.
[5] Ayelign B, Negash M, Genetu M, et al. Immunological impacts of diabetes on the susceptibility of mycobacterium tuberculosis[J]. J Immunol Res, 2019, 2019:6196532. DOI: 10.1155/2019/6196532.
[6] Maamar El Asri M, Pariente Rodrigo E, Díaz-Salazar de la Flor S, et al. Trabecular bone score and 25-hydroxyvitamin D levels in microvascular complications of type 2 diabetes mellitus[J]. Med Clin (Barc), 2022, 158(7):308-314. DOI: 10.1016/j.medcli.2021.04.027.
[7] Dineen R, Behan LA, Kelleher G, et al. The contribution of serum cortisone and glucocorticoid metabolites to detrimental bone health in patients receiving hydrocortisone therapy[J]. BMC Endocr Disord, 2020, 20(1):154. DOI: 10.1186/s12902-020-00633-1.
[8] Vilaca T, Paggiosi M, Walsh JS, et al. The effects of type 1 diabetes and diabetic peripheral neuropathy on the musculoskeletal system: a case-control study[J]. J Bone Miner Res, 2021, 36(6):1048-1059. DOI: 10.1002/jbmr.4271.
[9] Takei Y, Mori H, Sone H, et al. Polygon-like luminal configuration captured by intracoronary optical frequency domain imaging of a spontaneous coronary spasm in an ST-elevation myocardial infarction patient[J]. Coron Artery Dis, 2019, 30(4):314-315. DOI: 10.1097/MCA.0000000000000728.
[10] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中华糖尿病杂志,2018,10(1):4-67. DOI:10.3760/cma.j.issn.1674-5809.2018.01.003.
[11] Wehmeier PM, Fox T, Doerr JM, et al. Development and validation of a brief measure of self-management competence: the Self-Management Self-Test (SMST) [J]. Ther Innov Regul Sci, 2020, 54(3):534-543. DOI: 10.1007/s43441-019-00085-3.
[12] 牟丽娜,武晓玲,张俊岭,等.尼可地尔联合依那普利叶酸片对急性ST段抬高型心肌梗死患者急诊PCI术后左室重构及同型半胱氨酸的影响[J].中国老年学杂志,2020,40(2):231-235. DOI:10.3969/j.issn.1005-9202.2020.02.003.
[13] Reznik EV, Shcherbakova ES, Borisovskaya SV, et al. ST-elevation myocardial infarction, pulmonary embolism, and cerebral ischemic stroke in a patient with critically low levels of natural anticoagulants[J]. J Cardiol Cases, 2019, 21(3):106-109. DOI: 10.1016/j.jccase.2019.11.003.
[14] Varlamos C, Pappas C, Kiouri E, et al. Hyperhomocysteinemia as the only risk factor in a young man presenting with ST-elevation myocardial infarction[J]. J Cardiol Cases, 2020, 23(3):112-114. DOI: 10.1016/j.jccase.2020.10.004.
[15] Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis[J]. Lancet Diabetes Endocrinol, 2018, 6(2):105-113. DOI: 10.1016/S2213-8587(17)30412-6.
[16] Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus[J]. Circulation, 2019, 139(17):2022-2031. DOI: 10.1161/CIRCULATIONAHA.118. 038868.
[17] Okazaki H, Shirakabe A, Hata N, et al. New scoring system (APACHE-HF) for predicting adverse outcomes in patients with acute heart failure: evaluation of the APACHE II and Modified APACHE II scoring systems[J]. J Cardiol, 2014, 64(6):441-449. DOI: 10.1016/j.jjcc.2014.03.002.
[18] Fachri M, Hatta M, Abadi S, et al. Comparison of acid fast bacilli (AFB) smear for Mycobacterium tuberculosis on adult pulmonary tuberculosis (TB) patients with type 2 diabetes mellitus (DM) and without type 2 DM[J]. Respir Med Case Rep, 2018, 23:158-162. DOI: 10.1016/j.rmcr.2018.02.008.
[19] Figueira Gonçalves JM, García Bello MÁ, Golpe R, et al. Impact of diabetes mellitus on the risk of severe exacerbation in patients with chronic obstructive pulmonary disease[J]. Clin Respir J, 2020, 14(12):1208-1211. DOI: 10.1111/crj.13255.
[20] Sardu C, Gargiulo G, Esposito G, et al. Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19[J]. Cardiovasc Diabetol, 2020, 19(1):76. DOI: 10.1186/s12933-020-01047-y.
[21] Novita BD, Pranoto A, Wuryani, et al. A case risk study of lactic acidosis risk by metformin use in type 2 diabetes mellitus tuberculosis coinfection patients[J]. Indian J Tuberc, 2018, 65(3):252-256. DOI: 10.1016/j.ijtb.2017.05.008.
[22] Hove-Skovsgaard M, Abildgaard J, Gelpi M, et al. No evidence of a synergistic effect of HIV infection and diabetes mellitus type 2 on fat distribution, plasma adiponectin or inflammatory markers[J]. BMC Infect Dis, 2020, 20(1):882. DOI: 10.1186/s12879-020-05594-3.

尼可地尔联合二甲双胍治疗2型糖尿病合并冠心病患者的疗效和安全性观察

Efficacy and safety of nicorandil combined with metformin in the treatment of type 2 diabetes mellitus complicated with coronary heart disease

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	莫琳勤李杏张展苏严琳孙艳彬. 以格林模式为框架的强化护理模式在冠心病不稳定型心绞痛患者中的实践研究 [J]. 国际医药卫生导报, 2023, 29(8): 1160-1166.
[2]	陈吉业孙晓庆王相村卢波赵娟娟. 冠心病患者ABCB1、PON1、CYP2C19基因型检测及指导PCI术后精准用药的临床意义 [J]. 国际医药卫生导报, 2023, 29(7): 957-961.
[3]	颜波郑伟关祥平徐强钱玉军韩梅. 早发冠心病急性ST段抬高型心肌梗死患者冠脉病变特点及危险因素分析 [J]. 国际医药卫生导报, 2023, 29(4): 532-536.
[4]	刘晓卉. 小剂量硝酸甘油联合氯吡格雷治疗冠心病心绞痛患者的疗效及安全性评价 [J]. 国际医药卫生导报, 2023, 29(4): 549-553.
[5]	刘辉王珍珍赵亚非. 临床药师参与的用药管理对急性脑梗死介入术后患者用药规范性、用药依从性及安全性的影响 [J]. 国际医药卫生导报, 2023, 29(4): 564-568.
[6]	张建建康杰张宁辛杨明张伟. 瑞舒伐他汀联合达格列净治疗2型糖尿病合并冠心病的临床效果 [J]. 国际医药卫生导报, 2023, 29(3): 372-376.
[7]	任浩王惠林王磊. 血清淀粉样蛋白A联合胱抑素C、脂蛋白a对冠心病患者经皮冠状动脉介入治疗后冠状动脉再狭窄的预测价值 [J]. 国际医药卫生导报, 2023, 29(3): 419-423.
[8]	宋凡凡杨彩彩赵旭敏陈瑛李宇陈宇贾爱华. 身体测量指标及代谢指标对2型糖尿病患者合并非酒精性脂肪肝的诊断价值分析 [J]. 国际医药卫生导报, 2023, 29(1): 78-.
[9]	刘振, 孙经武, 张宁, 刘婧玚, 石新烨, 董文敬. 尿酸与心血管疾病的研究进展[J]. 国际医药卫生导报, 2022, 28(6): 884-888.
[10]	刘振, 孙经武, 张宁, 石新烨, 刘婧玚. RBP4与心血管疾病的研究进展[J]. 国际医药卫生导报, 2022, 28(4): 586-589.
[11]	陈香吴雪娟. 门诊协同护理联合认知重构干预对老年冠心病患者的效果分析[J]. 国际医药卫生导报, 2022, 28(24): 3461-.
[12]	朱晓艳韩萍. 中青年男性冠心病PCI术后患者及其配偶二元应对对生活质量的影响[J]. 国际医药卫生导报, 2022, 28(19): 2794-2800.
[13]	刘婧玚孙经武刘振石新烨董文敬. 衰老细胞清除剂在心血管疾病中的研究进展[J]. 国际医药卫生导报, 2022, 28(14): 2062-2065.
[14]	董文敬, 孙经武, 张宁, 刘振, 石新烨, 刘婧玚. 秋水仙碱在心血管疾病中应用的研究进展[J]. 国际医药卫生导报, 2022, 28(12): 1767-1771.
[15]	丁艳丽, 刘艳萍, 杨红蕾, 杨茹, 梁闪, 胡旭红, 袁晴川. 四级递增运动对体外膜肺氧合联合主动脉球囊反搏下高危冠心病行冠状动脉介入治疗的11例临床观察[J]. 国际医药卫生导报, 2022, 28(10): 1347-1351.